MedTrace Logo

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

NCT04885998 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-09-29

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of tarlatamab in combination with AMG 404.

Conditions

Interventions

DRUG

Tarlatamab

Tarlatamab will be administered as an intravenous (IV) infusion.

DRUG

AMG 404

AMG 404 will be administered as an intravenous (IV) infusion.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-27
Primary Completion
2023-07-12
Completion
2024-09-11
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Belgium
  • Japan
  • Singapore
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04885998 on ClinicalTrials.gov